You are here

Yasmin Mashhoon Nominated for 2016 Barbara J. McNeil Faculty Award

June 28, 2016 Print

Yasmin Mashhoon, PhD, a neuroscientist at McLean’s Behavioral Psychopharmacology Research Laboratory and assistant professor of psychiatry at Harvard Medical School (HMS), was recently nominated for the 2016 Barbara J. McNeil Faculty Award for Exceptional Institutional Service to HMS/HSDM.

The award was established in 2014 to recognize faculty for exceptional institutional engagement and service in supporting the missions of Harvard Medical School and Harvard School of Dental Medicine (HSDM). Mashhoon was nominated for serving as faculty chair of the Strategic Planning subcommittee of the HMS/HSDM Joint Committee on the Status of Women (JCSW). The JCSW supports professional career development and advancement of women at HMS and HSDM.

The JCSW Strategic Planning committee is developing a five-year plan to expand career advancement, leadership, and professional development opportunities and to elevate the visibility of the JCSW within the HMS/HSDM community, including McLean and Massachusetts General Hospital.

“The JCSW is aimed at promoting professional equity, leadership, and career development, as well as community building for women faculty, trainees, and staff at both HMS and HSDM and its affiliate hospitals,” said Mashhoon. “We’re putting a major emphasis on broadening the visibility of the influence of the JCSW by positioning ourselves as a committee of action,” she said. “There have been major institutional accomplishments that the JCSW has achieved, and we’re looking to increase the number of those accomplishments over the next few years.”

Mashhoon’s area of research at McLean focuses on utilizing multimodal imaging methods to measure drug-dependent changes in neural architecture—specifically changes in brain chemistry, electrophysiology, and structure. Her current projects involve explaining neurochemical, electrophysiological, and morphological alterations in adult brain architecture related to age of smoking onset during adolescent neurodevelopment.

“The goal,” she said, “is to use empirical evidence from these studies to help predict if treatment approaches should be differentially implemented in early versus late onset smokers to improve smoking cessation outcomes.”